nodes	percent_of_prediction	percent_of_DWPC	metapath
Amsacrine—CYP2D6—Hydroxyurea—psoriasis	0.091	0.179	CbGbCtD
Amsacrine—CYP2D6—Cholecalciferol—psoriasis	0.0551	0.108	CbGbCtD
Amsacrine—ABCB1—Mycophenolate mofetil—psoriasis	0.0507	0.0997	CbGbCtD
Amsacrine—ABCB1—Betamethasone—psoriasis	0.0435	0.0855	CbGbCtD
Amsacrine—ABCB1—Prednisolone—psoriasis	0.0429	0.0844	CbGbCtD
Amsacrine—ABCB1—Hydrocortisone—psoriasis	0.0407	0.08	CbGbCtD
Amsacrine—ABCB1—Prednisone—psoriasis	0.0405	0.0797	CbGbCtD
Amsacrine—ABCB1—Cyclosporine—psoriasis	0.0384	0.0756	CbGbCtD
Amsacrine—CYP2D6—Cyclosporine—psoriasis	0.0362	0.0712	CbGbCtD
Amsacrine—ABCB1—Dexamethasone—psoriasis	0.0253	0.0498	CbGbCtD
Amsacrine—CYP2D6—Dexamethasone—psoriasis	0.0238	0.0469	CbGbCtD
Amsacrine—ABCB1—Methotrexate—psoriasis	0.0203	0.04	CbGbCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—ZMIZ1—psoriasis	0.00371	0.0513	CbGpPWpGaD
Amsacrine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00355	0.049	CbGpPWpGaD
Amsacrine—NCOA3—Retinoic acid receptors-mediated signaling—VDR—psoriasis	0.00341	0.0471	CbGpPWpGaD
Amsacrine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00331	0.0457	CbGpPWpGaD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.00269	0.0371	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.00243	0.0336	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—CARM1—psoriasis	0.00239	0.033	CbGpPWpGaD
Amsacrine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.0022	0.0304	CbGpPWpGaD
Amsacrine—NCOA3—PPARA activates gene expression—CARM1—psoriasis	0.00202	0.0279	CbGpPWpGaD
Amsacrine—NCOA3—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.00198	0.0273	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—IL22—psoriasis	0.00187	0.0259	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	0.00165	0.0228	CbGpPWpGaD
Amsacrine—TOP2A—G0 and Early G1—PCNA—psoriasis	0.00154	0.0212	CbGpPWpGaD
Amsacrine—NCOA3—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.00136	0.0188	CbGpPWpGaD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	0.00128	0.0177	CbGpPWpGaD
Amsacrine—NCOA3—FOXA1 transcription factor network—JUN—psoriasis	0.00124	0.0171	CbGpPWpGaD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—PPARG—psoriasis	0.00112	0.0154	CbGpPWpGaD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—psoriasis	0.00104	0.0144	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	0.00092	0.0127	CbGpPWpGaD
Amsacrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000914	0.0126	CbGpPWpGaD
Amsacrine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000902	0.0124	CbGpPWpGaD
Amsacrine—TOP2A—Methyltestosterone—Hydrocortisone—psoriasis	0.000892	0.258	CbGdCrCtD
Amsacrine—NCOA3—PPARA activates gene expression—PPARG—psoriasis	0.000841	0.0116	CbGpPWpGaD
Amsacrine—NCOA3—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000823	0.0114	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—PCNA—psoriasis	0.000785	0.0108	CbGpPWpGaD
Amsacrine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000775	0.0107	CbGpPWpGaD
Amsacrine—TOP2A—Methyltestosterone—Prednisone—psoriasis	0.000768	0.222	CbGdCrCtD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	0.000764	0.0105	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000761	0.0105	CbGpPWpGaD
Amsacrine—TOP2A—Methyltestosterone—Prednisolone—psoriasis	0.00075	0.217	CbGdCrCtD
Amsacrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000741	0.0102	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000741	0.0102	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—JUN—psoriasis	0.000706	0.00975	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—STAT3—psoriasis	0.000611	0.00844	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—CARM1—psoriasis	0.000607	0.00838	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—IL13—psoriasis	0.0006	0.00829	CbGpPWpGaD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	0.000594	0.0082	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—NDUFA5—psoriasis	0.000582	0.00803	CbGpPWpGaD
Amsacrine—TOP2A—Norethindrone—Hydrocortisone—psoriasis	0.000581	0.168	CbGdCrCtD
Amsacrine—NCOA3—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000567	0.00783	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000566	0.00782	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000542	0.00749	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CYP2S1—psoriasis	0.000495	0.00683	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 2—TP53—psoriasis	0.000475	0.00656	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—JUN—psoriasis	0.000463	0.00639	CbGpPWpGaD
Amsacrine—TOP2A—Levonorgestrel—Hydrocortisone—psoriasis	0.000463	0.134	CbGdCrCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.00046	0.00635	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—NFKB1—psoriasis	0.000446	0.00615	CbGpPWpGaD
Amsacrine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000445	0.00615	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—JUN—psoriasis	0.000438	0.00604	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—VEGFA—psoriasis	0.000404	0.00558	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000398	0.0055	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000393	0.00543	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000388	0.00536	CbGpPWpGaD
Amsacrine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000381	0.00527	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—STAT3—psoriasis	0.000378	0.00522	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—IL10—psoriasis	0.000376	0.00519	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000359	0.00495	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000355	0.0049	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—IL13—psoriasis	0.000353	0.00487	CbGpPWpGaD
Amsacrine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—psoriasis	0.000343	0.00473	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000325	0.00448	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—PTTG1—psoriasis	0.000321	0.00443	CbGpPWpGaD
Amsacrine—Convulsion—Prednisolone—psoriasis	0.00032	0.00077	CcSEcCtD
Amsacrine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000316	0.000761	CcSEcCtD
Amsacrine—Arrhythmia—Dexamethasone—psoriasis	0.000316	0.000761	CcSEcCtD
Amsacrine—Arrhythmia—Betamethasone—psoriasis	0.000316	0.000761	CcSEcCtD
Amsacrine—Anorexia—Cyclosporine—psoriasis	0.000316	0.00076	CcSEcCtD
Amsacrine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000315	0.000759	CcSEcCtD
Amsacrine—Skin disorder—Mycophenolate mofetil—psoriasis	0.000314	0.000755	CcSEcCtD
Amsacrine—Bradycardia—Prednisone—psoriasis	0.000314	0.000755	CcSEcCtD
Amsacrine—Alopecia—Betamethasone—psoriasis	0.000313	0.000753	CcSEcCtD
Amsacrine—Alopecia—Dexamethasone—psoriasis	0.000313	0.000753	CcSEcCtD
Amsacrine—Convulsion—Hydrocortisone—psoriasis	0.000312	0.000752	CcSEcCtD
Amsacrine—Vomiting—Hydroxyurea—psoriasis	0.000311	0.000748	CcSEcCtD
Amsacrine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00031	0.00429	CbGpPWpGaD
Amsacrine—Haemoglobin—Prednisone—psoriasis	0.00031	0.000746	CcSEcCtD
Amsacrine—Haemorrhage—Prednisone—psoriasis	0.000308	0.000742	CcSEcCtD
Amsacrine—Rash—Hydroxyurea—psoriasis	0.000308	0.000742	CcSEcCtD
Amsacrine—Anorexia—Mycophenolate mofetil—psoriasis	0.000308	0.000741	CcSEcCtD
Amsacrine—Dermatitis—Hydroxyurea—psoriasis	0.000308	0.000741	CcSEcCtD
Amsacrine—Headache—Hydroxyurea—psoriasis	0.000306	0.000737	CcSEcCtD
Amsacrine—Pancytopenia—Methotrexate—psoriasis	0.000306	0.000736	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TP53—psoriasis	0.000306	0.00422	CbGpPWpGaD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000305	0.000734	CcSEcCtD
Amsacrine—Connective tissue disorder—Prednisone—psoriasis	0.000303	0.000729	CcSEcCtD
Amsacrine—Hypotension—Mycophenolate mofetil—psoriasis	0.000302	0.000727	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000302	0.00417	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000302	0.00417	CbGpPWpGaD
Amsacrine—Paraesthesia—Cyclosporine—psoriasis	0.000297	0.000716	CcSEcCtD
Amsacrine—Dyspnoea—Cyclosporine—psoriasis	0.000295	0.000711	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000295	0.00407	CbGpPWpGaD
Amsacrine—Convulsion—Triamcinolone—psoriasis	0.000294	0.000708	CcSEcCtD
Amsacrine—Tachycardia—Prednisolone—psoriasis	0.000294	0.000708	CcSEcCtD
Amsacrine—Asthenia—Mycophenolic acid—psoriasis	0.000294	0.000707	CcSEcCtD
Amsacrine—Infection—Hydrocortisone—psoriasis	0.000292	0.000704	CcSEcCtD
Amsacrine—Nausea—Hydroxyurea—psoriasis	0.00029	0.000699	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—LEP—psoriasis	0.00029	0.00401	CbGpPWpGaD
Amsacrine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.00029	0.000698	CcSEcCtD
Amsacrine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000288	0.000693	CcSEcCtD
Amsacrine—Decreased appetite—Cyclosporine—psoriasis	0.000288	0.000693	CcSEcCtD
Amsacrine—Tachycardia—Hydrocortisone—psoriasis	0.000287	0.000691	CcSEcCtD
Amsacrine—Infestation—Methotrexate—psoriasis	0.000287	0.000691	CcSEcCtD
Amsacrine—Infestation NOS—Methotrexate—psoriasis	0.000287	0.000691	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000286	0.000688	CcSEcCtD
Amsacrine—Skin disorder—Hydrocortisone—psoriasis	0.000286	0.000688	CcSEcCtD
Amsacrine—Fatigue—Cyclosporine—psoriasis	0.000286	0.000687	CcSEcCtD
Amsacrine—Pain—Cyclosporine—psoriasis	0.000283	0.000682	CcSEcCtD
Amsacrine—Renal failure—Methotrexate—psoriasis	0.000282	0.000679	CcSEcCtD
Amsacrine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000281	0.000676	CcSEcCtD
Amsacrine—Anorexia—Hydrocortisone—psoriasis	0.000281	0.000675	CcSEcCtD
Amsacrine—Diarrhoea—Mycophenolic acid—psoriasis	0.00028	0.000674	CcSEcCtD
Amsacrine—Stomatitis—Methotrexate—psoriasis	0.00028	0.000673	CcSEcCtD
Amsacrine—Angiopathy—Prednisone—psoriasis	0.00028	0.000673	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000279	0.000671	CcSEcCtD
Amsacrine—Pain—Mycophenolate mofetil—psoriasis	0.000276	0.000665	CcSEcCtD
Amsacrine—Arrhythmia—Prednisone—psoriasis	0.000275	0.000663	CcSEcCtD
Amsacrine—Infection—Triamcinolone—psoriasis	0.000275	0.000663	CcSEcCtD
Amsacrine—Hypotension—Hydrocortisone—psoriasis	0.000275	0.000662	CcSEcCtD
Amsacrine—Haematuria—Methotrexate—psoriasis	0.000274	0.000659	CcSEcCtD
Amsacrine—Feeling abnormal—Cyclosporine—psoriasis	0.000273	0.000657	CcSEcCtD
Amsacrine—Alopecia—Prednisone—psoriasis	0.000272	0.000656	CcSEcCtD
Amsacrine—Hepatobiliary disease—Methotrexate—psoriasis	0.000271	0.000653	CcSEcCtD
Amsacrine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000271	0.000652	CcSEcCtD
Amsacrine—Dizziness—Mycophenolic acid—psoriasis	0.000271	0.000652	CcSEcCtD
Amsacrine—Paraesthesia—Prednisolone—psoriasis	0.000271	0.000651	CcSEcCtD
Amsacrine—Tachycardia—Triamcinolone—psoriasis	0.00027	0.000651	CcSEcCtD
Amsacrine—Mental disorder—Prednisone—psoriasis	0.00027	0.00065	CcSEcCtD
Amsacrine—Malnutrition—Prednisone—psoriasis	0.000268	0.000646	CcSEcCtD
Amsacrine—Agranulocytosis—Methotrexate—psoriasis	0.000268	0.000645	CcSEcCtD
Amsacrine—Convulsion—Betamethasone—psoriasis	0.000267	0.000643	CcSEcCtD
Amsacrine—Convulsion—Dexamethasone—psoriasis	0.000267	0.000643	CcSEcCtD
Amsacrine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000266	0.000641	CcSEcCtD
Amsacrine—Paraesthesia—Hydrocortisone—psoriasis	0.000264	0.000636	CcSEcCtD
Amsacrine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000264	0.000636	CcSEcCtD
Amsacrine—Urticaria—Cyclosporine—psoriasis	0.000263	0.000633	CcSEcCtD
Amsacrine—Body temperature increased—Cyclosporine—psoriasis	0.000262	0.00063	CcSEcCtD
Amsacrine—Abdominal pain—Cyclosporine—psoriasis	0.000262	0.00063	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—LEP—psoriasis	0.000261	0.00361	CbGpPWpGaD
Amsacrine—Vomiting—Mycophenolic acid—psoriasis	0.00026	0.000627	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000259	0.00358	CbGpPWpGaD
Amsacrine—Haemoglobin—Methotrexate—psoriasis	0.000259	0.000623	CcSEcCtD
Amsacrine—Rash—Mycophenolic acid—psoriasis	0.000258	0.000621	CcSEcCtD
Amsacrine—Dermatitis—Mycophenolic acid—psoriasis	0.000258	0.000621	CcSEcCtD
Amsacrine—Pain—Prednisolone—psoriasis	0.000258	0.00062	CcSEcCtD
Amsacrine—Hepatitis—Methotrexate—psoriasis	0.000258	0.00062	CcSEcCtD
Amsacrine—Haemorrhage—Methotrexate—psoriasis	0.000258	0.00062	CcSEcCtD
Amsacrine—Urticaria—Mycophenolate mofetil—psoriasis	0.000257	0.000618	CcSEcCtD
Amsacrine—Headache—Mycophenolic acid—psoriasis	0.000256	0.000617	CcSEcCtD
Amsacrine—Decreased appetite—Hydrocortisone—psoriasis	0.000256	0.000616	CcSEcCtD
Amsacrine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000255	0.000615	CcSEcCtD
Amsacrine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000255	0.000615	CcSEcCtD
Amsacrine—Urinary tract disorder—Methotrexate—psoriasis	0.000254	0.000612	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000254	0.000612	CcSEcCtD
Amsacrine—Fatigue—Hydrocortisone—psoriasis	0.000254	0.000611	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000254	0.0035	CbGpPWpGaD
Amsacrine—Vision blurred—Prednisone—psoriasis	0.000253	0.000609	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—PPARG—psoriasis	0.000253	0.00349	CbGpPWpGaD
Amsacrine—Urethral disorder—Methotrexate—psoriasis	0.000253	0.000608	CcSEcCtD
Amsacrine—Pain—Hydrocortisone—psoriasis	0.000252	0.000606	CcSEcCtD
Amsacrine—Infection—Dexamethasone—psoriasis	0.00025	0.000601	CcSEcCtD
Amsacrine—Infection—Betamethasone—psoriasis	0.00025	0.000601	CcSEcCtD
Amsacrine—Paraesthesia—Triamcinolone—psoriasis	0.000249	0.000599	CcSEcCtD
Amsacrine—Feeling abnormal—Prednisolone—psoriasis	0.000248	0.000598	CcSEcCtD
Amsacrine—Anaemia—Prednisone—psoriasis	0.000248	0.000597	CcSEcCtD
Amsacrine—Dyspnoea—Triamcinolone—psoriasis	0.000247	0.000595	CcSEcCtD
Amsacrine—Thrombocytopenia—Dexamethasone—psoriasis	0.000246	0.000593	CcSEcCtD
Amsacrine—Thrombocytopenia—Betamethasone—psoriasis	0.000246	0.000593	CcSEcCtD
Amsacrine—Tachycardia—Dexamethasone—psoriasis	0.000245	0.000591	CcSEcCtD
Amsacrine—Tachycardia—Betamethasone—psoriasis	0.000245	0.000591	CcSEcCtD
Amsacrine—Hypersensitivity—Cyclosporine—psoriasis	0.000244	0.000587	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000244	0.00337	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—NOS2—psoriasis	0.000243	0.00336	CbGpPWpGaD
Amsacrine—Nausea—Mycophenolic acid—psoriasis	0.000243	0.000585	CcSEcCtD
Amsacrine—Feeling abnormal—Hydrocortisone—psoriasis	0.000243	0.000584	CcSEcCtD
Amsacrine—NCOA3—Metabolism—CARM1—psoriasis	0.000242	0.00333	CbGpPWpGaD
Amsacrine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000241	0.000579	CcSEcCtD
Amsacrine—Anorexia—Dexamethasone—psoriasis	0.00024	0.000577	CcSEcCtD
Amsacrine—Anorexia—Betamethasone—psoriasis	0.00024	0.000577	CcSEcCtD
Amsacrine—Urticaria—Prednisolone—psoriasis	0.000239	0.000576	CcSEcCtD
Amsacrine—Cardiac disorder—Methotrexate—psoriasis	0.000239	0.000576	CcSEcCtD
Amsacrine—Fatigue—Triamcinolone—psoriasis	0.000239	0.000575	CcSEcCtD
Amsacrine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000238	0.000573	CcSEcCtD
Amsacrine—Asthenia—Cyclosporine—psoriasis	0.000238	0.000572	CcSEcCtD
Amsacrine—Pain—Triamcinolone—psoriasis	0.000237	0.00057	CcSEcCtD
Amsacrine—Hypotension—Dexamethasone—psoriasis	0.000235	0.000566	CcSEcCtD
Amsacrine—Hypotension—Betamethasone—psoriasis	0.000235	0.000566	CcSEcCtD
Amsacrine—Urticaria—Hydrocortisone—psoriasis	0.000234	0.000563	CcSEcCtD
Amsacrine—Angiopathy—Methotrexate—psoriasis	0.000234	0.000563	CcSEcCtD
Amsacrine—Abdominal pain—Hydrocortisone—psoriasis	0.000233	0.00056	CcSEcCtD
Amsacrine—Body temperature increased—Hydrocortisone—psoriasis	0.000233	0.00056	CcSEcCtD
Amsacrine—Convulsion—Prednisone—psoriasis	0.000232	0.00056	CcSEcCtD
Amsacrine—Mediastinal disorder—Methotrexate—psoriasis	0.000232	0.000559	CcSEcCtD
Amsacrine—Asthenia—Mycophenolate mofetil—psoriasis	0.000232	0.000558	CcSEcCtD
Amsacrine—Feeling abnormal—Triamcinolone—psoriasis	0.000228	0.00055	CcSEcCtD
Amsacrine—Alopecia—Methotrexate—psoriasis	0.000228	0.000548	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—PPARG—psoriasis	0.000228	0.00314	CbGpPWpGaD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000227	0.000546	CcSEcCtD
Amsacrine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000227	0.00313	CbGpPWpGaD
Amsacrine—Diarrhoea—Cyclosporine—psoriasis	0.000227	0.000545	CcSEcCtD
Amsacrine—Paraesthesia—Betamethasone—psoriasis	0.000226	0.000544	CcSEcCtD
Amsacrine—Paraesthesia—Dexamethasone—psoriasis	0.000226	0.000544	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000226	0.00312	CbGpPWpGaD
Amsacrine—Mental disorder—Methotrexate—psoriasis	0.000226	0.000543	CcSEcCtD
Amsacrine—Malnutrition—Methotrexate—psoriasis	0.000224	0.00054	CcSEcCtD
Amsacrine—Hypersensitivity—Prednisolone—psoriasis	0.000222	0.000534	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—TYK2—psoriasis	0.000222	0.00306	CbGpPWpGaD
Amsacrine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000221	0.000532	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—IL10—psoriasis	0.000221	0.00305	CbGpPWpGaD
Amsacrine—Urticaria—Triamcinolone—psoriasis	0.00022	0.00053	CcSEcCtD
Amsacrine—Body temperature increased—Triamcinolone—psoriasis	0.000219	0.000527	CcSEcCtD
Amsacrine—Dizziness—Cyclosporine—psoriasis	0.000219	0.000527	CcSEcCtD
Amsacrine—Decreased appetite—Betamethasone—psoriasis	0.000219	0.000526	CcSEcCtD
Amsacrine—Decreased appetite—Dexamethasone—psoriasis	0.000219	0.000526	CcSEcCtD
Amsacrine—Infection—Prednisone—psoriasis	0.000218	0.000524	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000217	0.000523	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000217	0.000523	CcSEcCtD
Amsacrine—Hypersensitivity—Hydrocortisone—psoriasis	0.000217	0.000522	CcSEcCtD
Amsacrine—Fatigue—Dexamethasone—psoriasis	0.000217	0.000522	CcSEcCtD
Amsacrine—Fatigue—Betamethasone—psoriasis	0.000217	0.000522	CcSEcCtD
Amsacrine—Pain—Dexamethasone—psoriasis	0.000215	0.000518	CcSEcCtD
Amsacrine—Pain—Betamethasone—psoriasis	0.000215	0.000518	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—IL4—psoriasis	0.000215	0.00296	CbGpPWpGaD
Amsacrine—Tachycardia—Prednisone—psoriasis	0.000214	0.000514	CcSEcCtD
Amsacrine—Dizziness—Mycophenolate mofetil—psoriasis	0.000214	0.000514	CcSEcCtD
Amsacrine—Skin disorder—Prednisone—psoriasis	0.000213	0.000512	CcSEcCtD
Amsacrine—Vision blurred—Methotrexate—psoriasis	0.000211	0.000509	CcSEcCtD
Amsacrine—Asthenia—Hydrocortisone—psoriasis	0.000211	0.000508	CcSEcCtD
Amsacrine—Vomiting—Cyclosporine—psoriasis	0.000211	0.000507	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—HLA-B—psoriasis	0.00021	0.0029	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	0.00021	0.00289	CbGpPWpGaD
Amsacrine—Rash—Cyclosporine—psoriasis	0.000209	0.000503	CcSEcCtD
Amsacrine—Anorexia—Prednisone—psoriasis	0.000209	0.000502	CcSEcCtD
Amsacrine—Dermatitis—Cyclosporine—psoriasis	0.000209	0.000502	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000208	0.00287	CbGpPWpGaD
Amsacrine—Headache—Cyclosporine—psoriasis	0.000207	0.000499	CcSEcCtD
Amsacrine—Anaemia—Methotrexate—psoriasis	0.000207	0.000499	CcSEcCtD
Amsacrine—Feeling abnormal—Betamethasone—psoriasis	0.000207	0.000499	CcSEcCtD
Amsacrine—Feeling abnormal—Dexamethasone—psoriasis	0.000207	0.000499	CcSEcCtD
Amsacrine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000206	0.000495	CcSEcCtD
Amsacrine—Gastrointestinal pain—Betamethasone—psoriasis	0.000206	0.000495	CcSEcCtD
Amsacrine—Vomiting—Mycophenolate mofetil—psoriasis	0.000205	0.000494	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000205	0.00283	CbGpPWpGaD
Amsacrine—Hypersensitivity—Triamcinolone—psoriasis	0.000204	0.000492	CcSEcCtD
Amsacrine—Rash—Mycophenolate mofetil—psoriasis	0.000204	0.00049	CcSEcCtD
Amsacrine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000204	0.00049	CcSEcCtD
Amsacrine—Headache—Mycophenolate mofetil—psoriasis	0.000202	0.000487	CcSEcCtD
Amsacrine—Diarrhoea—Hydrocortisone—psoriasis	0.000201	0.000485	CcSEcCtD
Amsacrine—Leukopenia—Methotrexate—psoriasis	0.000201	0.000483	CcSEcCtD
Amsacrine—Urticaria—Betamethasone—psoriasis	0.0002	0.000481	CcSEcCtD
Amsacrine—Urticaria—Dexamethasone—psoriasis	0.0002	0.000481	CcSEcCtD
Amsacrine—Dizziness—Prednisolone—psoriasis	0.000199	0.00048	CcSEcCtD
Amsacrine—Asthenia—Triamcinolone—psoriasis	0.000199	0.000479	CcSEcCtD
Amsacrine—Abdominal pain—Betamethasone—psoriasis	0.000199	0.000479	CcSEcCtD
Amsacrine—Abdominal pain—Dexamethasone—psoriasis	0.000199	0.000479	CcSEcCtD
Amsacrine—Body temperature increased—Dexamethasone—psoriasis	0.000199	0.000479	CcSEcCtD
Amsacrine—Body temperature increased—Betamethasone—psoriasis	0.000199	0.000479	CcSEcCtD
Amsacrine—Nausea—Cyclosporine—psoriasis	0.000197	0.000474	CcSEcCtD
Amsacrine—Paraesthesia—Prednisone—psoriasis	0.000197	0.000473	CcSEcCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000195	0.0027	CbGpPWpGaD
Amsacrine—Dizziness—Hydrocortisone—psoriasis	0.000195	0.000469	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—HLA-A—psoriasis	0.000195	0.00269	CbGpPWpGaD
Amsacrine—Convulsion—Methotrexate—psoriasis	0.000194	0.000468	CcSEcCtD
Amsacrine—Nausea—Mycophenolate mofetil—psoriasis	0.000192	0.000462	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	0.000191	0.00264	CbGpPWpGaD
Amsacrine—Decreased appetite—Prednisone—psoriasis	0.00019	0.000458	CcSEcCtD
Amsacrine—Rash—Prednisolone—psoriasis	0.00019	0.000457	CcSEcCtD
Amsacrine—Dermatitis—Prednisolone—psoriasis	0.00019	0.000457	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00019	0.000456	CcSEcCtD
Amsacrine—Fatigue—Prednisone—psoriasis	0.000189	0.000454	CcSEcCtD
Amsacrine—Headache—Prednisolone—psoriasis	0.000189	0.000454	CcSEcCtD
Amsacrine—Vomiting—Hydrocortisone—psoriasis	0.000187	0.00045	CcSEcCtD
Amsacrine—Rash—Hydrocortisone—psoriasis	0.000186	0.000447	CcSEcCtD
Amsacrine—Dermatitis—Hydrocortisone—psoriasis	0.000185	0.000446	CcSEcCtD
Amsacrine—Confusional state—Methotrexate—psoriasis	0.000185	0.000444	CcSEcCtD
Amsacrine—Headache—Hydrocortisone—psoriasis	0.000184	0.000444	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000184	0.00254	CbGpPWpGaD
Amsacrine—Dizziness—Triamcinolone—psoriasis	0.000183	0.000441	CcSEcCtD
Amsacrine—Infection—Methotrexate—psoriasis	0.000182	0.000438	CcSEcCtD
Amsacrine—Feeling abnormal—Prednisone—psoriasis	0.00018	0.000434	CcSEcCtD
Amsacrine—Asthenia—Betamethasone—psoriasis	0.00018	0.000434	CcSEcCtD
Amsacrine—Asthenia—Dexamethasone—psoriasis	0.00018	0.000434	CcSEcCtD
Amsacrine—Thrombocytopenia—Methotrexate—psoriasis	0.000179	0.000431	CcSEcCtD
Amsacrine—Gastrointestinal pain—Prednisone—psoriasis	0.000179	0.000431	CcSEcCtD
Amsacrine—Nausea—Prednisolone—psoriasis	0.000179	0.000431	CcSEcCtD
Amsacrine—Skin disorder—Methotrexate—psoriasis	0.000178	0.000428	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	0.000178	0.00245	CbGpPWpGaD
Amsacrine—Vomiting—Triamcinolone—psoriasis	0.000176	0.000424	CcSEcCtD
Amsacrine—Nausea—Hydrocortisone—psoriasis	0.000175	0.000421	CcSEcCtD
Amsacrine—Rash—Triamcinolone—psoriasis	0.000175	0.000421	CcSEcCtD
Amsacrine—Dermatitis—Triamcinolone—psoriasis	0.000175	0.00042	CcSEcCtD
Amsacrine—Anorexia—Methotrexate—psoriasis	0.000174	0.00042	CcSEcCtD
Amsacrine—Urticaria—Prednisone—psoriasis	0.000174	0.000419	CcSEcCtD
Amsacrine—Headache—Triamcinolone—psoriasis	0.000174	0.000418	CcSEcCtD
Amsacrine—Abdominal pain—Prednisone—psoriasis	0.000173	0.000417	CcSEcCtD
Amsacrine—Body temperature increased—Prednisone—psoriasis	0.000173	0.000417	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—NFKB1—psoriasis	0.000173	0.00238	CbGpPWpGaD
Amsacrine—Diarrhoea—Dexamethasone—psoriasis	0.000172	0.000414	CcSEcCtD
Amsacrine—Diarrhoea—Betamethasone—psoriasis	0.000172	0.000414	CcSEcCtD
Amsacrine—Hypotension—Methotrexate—psoriasis	0.000171	0.000412	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000168	0.00232	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000167	0.0023	CbGpPWpGaD
Amsacrine—Dizziness—Betamethasone—psoriasis	0.000166	0.0004	CcSEcCtD
Amsacrine—Dizziness—Dexamethasone—psoriasis	0.000166	0.0004	CcSEcCtD
Amsacrine—Nausea—Triamcinolone—psoriasis	0.000165	0.000396	CcSEcCtD
Amsacrine—Paraesthesia—Methotrexate—psoriasis	0.000164	0.000396	CcSEcCtD
Amsacrine—Dyspnoea—Methotrexate—psoriasis	0.000163	0.000393	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000162	0.00223	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—JUN—psoriasis	0.000161	0.00223	CbGpPWpGaD
Amsacrine—Hypersensitivity—Prednisone—psoriasis	0.000161	0.000388	CcSEcCtD
Amsacrine—Vomiting—Betamethasone—psoriasis	0.00016	0.000385	CcSEcCtD
Amsacrine—Vomiting—Dexamethasone—psoriasis	0.00016	0.000385	CcSEcCtD
Amsacrine—Decreased appetite—Methotrexate—psoriasis	0.000159	0.000383	CcSEcCtD
Amsacrine—Rash—Betamethasone—psoriasis	0.000159	0.000382	CcSEcCtD
Amsacrine—Rash—Dexamethasone—psoriasis	0.000159	0.000382	CcSEcCtD
Amsacrine—Dermatitis—Dexamethasone—psoriasis	0.000158	0.000381	CcSEcCtD
Amsacrine—Dermatitis—Betamethasone—psoriasis	0.000158	0.000381	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000158	0.00038	CcSEcCtD
Amsacrine—Fatigue—Methotrexate—psoriasis	0.000158	0.00038	CcSEcCtD
Amsacrine—Headache—Betamethasone—psoriasis	0.000158	0.000379	CcSEcCtD
Amsacrine—Headache—Dexamethasone—psoriasis	0.000158	0.000379	CcSEcCtD
Amsacrine—Asthenia—Prednisone—psoriasis	0.000157	0.000378	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—VEGFA—psoriasis	0.000157	0.00216	CbGpPWpGaD
Amsacrine—Pain—Methotrexate—psoriasis	0.000157	0.000377	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—STAT3—psoriasis	0.000155	0.00214	CbGpPWpGaD
Amsacrine—Feeling abnormal—Methotrexate—psoriasis	0.000151	0.000363	CcSEcCtD
Amsacrine—Diarrhoea—Prednisone—psoriasis	0.00015	0.000361	CcSEcCtD
Amsacrine—Gastrointestinal pain—Methotrexate—psoriasis	0.00015	0.00036	CcSEcCtD
Amsacrine—Nausea—Betamethasone—psoriasis	0.000149	0.00036	CcSEcCtD
Amsacrine—Nausea—Dexamethasone—psoriasis	0.000149	0.00036	CcSEcCtD
Amsacrine—NCOA3—Metabolism—CAT—psoriasis	0.000149	0.00205	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	0.000147	0.00203	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—PCNA—psoriasis	0.000146	0.00202	CbGpPWpGaD
Amsacrine—Urticaria—Methotrexate—psoriasis	0.000145	0.00035	CcSEcCtD
Amsacrine—Dizziness—Prednisone—psoriasis	0.000145	0.000349	CcSEcCtD
Amsacrine—Body temperature increased—Methotrexate—psoriasis	0.000145	0.000348	CcSEcCtD
Amsacrine—Abdominal pain—Methotrexate—psoriasis	0.000145	0.000348	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	0.000143	0.00197	CbGpPWpGaD
Amsacrine—Vomiting—Prednisone—psoriasis	0.000139	0.000335	CcSEcCtD
Amsacrine—Rash—Prednisone—psoriasis	0.000138	0.000332	CcSEcCtD
Amsacrine—Dermatitis—Prednisone—psoriasis	0.000138	0.000332	CcSEcCtD
Amsacrine—Headache—Prednisone—psoriasis	0.000137	0.00033	CcSEcCtD
Amsacrine—Hypersensitivity—Methotrexate—psoriasis	0.000135	0.000325	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—TNF—psoriasis	0.000134	0.00185	CbGpPWpGaD
Amsacrine—Asthenia—Methotrexate—psoriasis	0.000131	0.000316	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—PCNA—psoriasis	0.000131	0.0018	CbGpPWpGaD
Amsacrine—Nausea—Prednisone—psoriasis	0.00013	0.000313	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—IFNG—psoriasis	0.00013	0.00179	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	0.00013	0.00179	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	0.000126	0.00174	CbGpPWpGaD
Amsacrine—Diarrhoea—Methotrexate—psoriasis	0.000125	0.000301	CcSEcCtD
Amsacrine—Dizziness—Methotrexate—psoriasis	0.000121	0.000291	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—CXCL8—psoriasis	0.000121	0.00167	CbGpPWpGaD
Amsacrine—Vomiting—Methotrexate—psoriasis	0.000116	0.00028	CcSEcCtD
Amsacrine—NCOA3—Metabolism—APOE—psoriasis	0.000115	0.00159	CbGpPWpGaD
Amsacrine—Rash—Methotrexate—psoriasis	0.000115	0.000278	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	0.000115	0.00159	CbGpPWpGaD
Amsacrine—Dermatitis—Methotrexate—psoriasis	0.000115	0.000278	CcSEcCtD
Amsacrine—Headache—Methotrexate—psoriasis	0.000115	0.000276	CcSEcCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	0.000113	0.00156	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	0.000111	0.00153	CbGpPWpGaD
Amsacrine—Nausea—Methotrexate—psoriasis	0.000109	0.000262	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—IL6—psoriasis	0.000108	0.0015	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—TP53—psoriasis	0.000107	0.00147	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PPARG—psoriasis	0.000101	0.00139	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	9.94e-05	0.00137	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—VEGFA—psoriasis	9.8e-05	0.00135	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—IL6—psoriasis	9.75e-05	0.00135	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—TNF—psoriasis	8.4e-05	0.00116	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NDUFA5—psoriasis	8.4e-05	0.00116	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	8.35e-05	0.00115	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NDUFA5—psoriasis	7.91e-05	0.00109	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	7.8e-05	0.00108	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	7.45e-05	0.00103	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CYP2S1—psoriasis	7.14e-05	0.000986	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CYP2S1—psoriasis	6.73e-05	0.000929	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.54e-05	0.000764	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	5.33e-05	0.000736	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.84e-05	0.000668	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TP53—psoriasis	4.8e-05	0.000663	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	4.15e-05	0.000572	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.65e-05	0.000504	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CARM1—psoriasis	3.49e-05	0.000481	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CARM1—psoriasis	3.29e-05	0.000454	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CAT—psoriasis	2.14e-05	0.000296	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CAT—psoriasis	2.02e-05	0.000279	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—APOE—psoriasis	1.67e-05	0.00023	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—APOE—psoriasis	1.57e-05	0.000217	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PPARG—psoriasis	1.45e-05	0.0002	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PPARG—psoriasis	1.37e-05	0.000189	CbGpPWpGaD
